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Abstract
Background. In patients with multiple myeloma (MM) there is a high risk of compression fractures of the spine. 
In the majority of cases, the method of treatment is percutaneous vertebroplasty (PV) or kyphoplasty (PK). The 
number of studies verifying their efficacy in MM is still relatively small.
Objectives. The aim of this study has been to assess medium- and long-term pain relief as well as improvement in 
the quality of life (QL) after PV in MM cases.
Material and Methods. There was a prospective group of 34 MM cases in which a total of 131 vertebral bodies were 
augmented by means of PV. It was possible to follow up 22 patients who agreed to take part in the assessment. Their 
level of daily activity and the level of pain were assessed using the Oswestry Back Pain scale and a visual analogue 
scale (VAS) before PV and at a later date (medium-term follow up was a mean of 10 months after the last operation). 
Five out of eight cases in which 4.5–5 years had elapsed since the first PV were tested again (long-term follow-up).
Results. Relief of pain and improvement of QL, assessed a mean of 10 months after PV, proved to be statistically 
significant. On the average, pain decreased by 4.7 points as measured on the VAS scale and the average improve-
ment in the QL measured on the Oswestry scale was 27.7%. There were no neurological or general complications. 
After 4.5–5 years, there has not been any significant change in the level of pain relief or the improvement in the QL 
in the 5 cases in which long-term assessment was possible.
Conclusions. In MM cases, PV is a simple, effective and safe method for the treatment of vertebral infiltration and 
compression fractures, giving permanent long-term pain relief and concomitant improvement in the QL (Adv Clin 
Exp Med 2015, 24, 4, 651–656).
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Percutaneous vertebroplasty (PV) is a  meth-
od of injecting polymethylmetacrylate cement 
(PMMA) into a  collapsing vertebral body. PV 
was developed in the late 1980s and was first de-
scribed in 1987 by Galibert and Deramond for 
the treatment of a  hemangioma of the C2 verte-
bral body  [1]. Percutaneous kyphoplasty (PK) 
is a  modified augmentation technique in which 
a  space for the cement is prepared beforehand, 
using an inflated balloon. The expected potential 
advantage of PK was that the restoration of verte-
bral height by means of a balloon would improve 
the axis of the vertebral column and therefore re-
duce the angle of kyphosis  [2]. Regardless of the 
method used, PMMA augmentation of the verte-
bra seems to be a  perfectly reasonable procedure 
when the aim is to prevent spinal disability in os-
teoporotic fractures, selected traumatic compres-
sion fractures, vertebral metastases and multiple 
myeloma (MM) infiltration.
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Depending on their severity, vertebral lesions 
can produce various signs: kyphosis of the thorac-
ic spine may manifest itself in local and/or radicu-
lar pain followed by hypoventilation, while kypho-
sis in the lumbar region may give rise to local pain 
or signs of compression. Pain radiating around the 
abdomen can cause increased abdominal pressure, 
and in advanced cases can lead to malnutrition. 
The aim of PV/PK treatment is to relieve pain and 
prevent any further deformation of the spine. It is 
the accompanying exothermic reaction that is re-
sponsible for the pain relief brought about by the 
use of this technique. In neoplastic cases, shrink-
age of the tumor mass and potential prevention of 
proliferation are also significant treatment factors. 
Primary infiltration of the vertebra occurs quite of-
ten in MM, and in about 30% of cases can lead to 
compression fractures [2]. As improvements in the 
effectiveness of MM treatment are prolonging the 
lives of these patients, it is increasingly important 
to ensure pain relief and stability of the spine in or-
der to achieve better quality of life (QL). Improved 
QL also contributes to the patient’s ability to main-
tain a positive attitude in the fight against MM and 
a good tolerance of chemotherapy.
Although PV and PK are used quite frequent-
ly, the number of studies verifying their efficacy 
in MM is still relatively small. The post-procedure 
follow-up time is usually between 6 months and 
1 year – rarely longer – but no more than 4 years.
The aim of the present study was to assess me-
dium- and long-term pain relief as well as the im-
provement of the quality of life after PV in a series 
of MM cases involving vertebral fractures.
Material and Methods
There was a prospective group of 34 MM cas-
es in which a  total of 131 vertebral bodies were 
augmented by means of PV. Seven cases were ex-
cluded from the study, as death occurred before 
the completion of follow-up owing to the progres-
sion of the disease. Of the remaining 27  patients 
(81.5% of the original number), 22 responded to 
a request to take part in the assessment (medium- 
-term follow-up between 6 and 18 months – a mean 
of 10  months after the last surgical procedure): 
11 males and 11 females aged between 38 and 79, 
the average being 61. To date, another 7 patients 
have died. In 8 of the remaining 15 patients, 4.5 to 
5 years have elapsed since the last PV. Five patients 
responded to a request to take part in further (i.e. 
long-term) assessment.
Using the Oswestry and visual analogue (VAS) 
scales, levels of life activity and pain were assessed 
by means of relevant questionnaires before surgery 
and in the medium- and long-term periods [3]. The 
results were subjected to statistical analysis. Nor-
mal distribution of variables was checked using the 
Shapiro-Wilk test. The t test was used to compare 
2 dependent groups with a normal distribution of 
dependent variables. The Wilcoxon test was used 
to compare 2 dependent groups if normality was 
not observed. The Friedman test was used to com-
pare 3 dependent groups without a normal distri-
bution of variables. Results with a  p-value of less 
than 0.05 were considered statistically significant.
All the calculations were performed using 
STATISTICA 10 PL software (StatSoft, Inc., USA), 
licensed to Jagiellonian University, Kraków.
In all cases, the PV procedures were performed 
under local anesthesia and neuroleptic analge-
sia (NLA). Under biplanar fluoroscopic control, 
a  one- or two-portal approach was used, via the 
extrapedicular or transpedicular route, respective-
ly. In most cases, a unilateral approach was suffi-
cient. It was of paramount importance to reach the 
anterior third of the vertebra with the tip of the 
needle — close to the midline, using the unilateral 
approach (in the A-P view), and symmetrically, us-
ing the bilateral approach. The injection volume of 
PMMA ranged from 4 to 7 mL, depending on the 
size of the vertebra and the level of the vertebral 
column: a lesser volume is needed for the thorac-
ic spine and a greater volume for the lumbar spine. 
The procedures were carried out using Synicem® 
(Biomet), Confidence® (Johnson) and Autoplex® 
(Stryker) sets. The procedure was halted when 
leakage was observed outside the vertebra, and was 
restarted 1 or 2 min later. It was possible to carry 
out an augmentation of between 1 and 4 vertebral 
bodies during one session. The patients were able 
to stand up on the day of the surgery. Standard an-
tibiotics and anticoagulants were administered in-
travenously in prophylactic doses. The number of 
sessions varied from 1 to 5, and the augmented lev-
els from 1 to 11.
Results
At the beginning of the assessment, most of the 
22 patients reported intense pain which greatly im-
paired the quality of their lives, preventing them 
from performing basic daily activities. The reported 
values varied from 12% to 98% (a mean of 56.6%) 
on the Oswestry scale and from 3.4 to 10 points 
(a  mean of 7.8) on the VAS scale. Three patients 
were unable to get out of bed without assistance.
At the medium-term follow-up (a  mean of 
10 months after surgery) in 19 out of 22 cases, sig-
nificant pain relief according to the Oswestry scale 
was observed, accompanied by an improvement in 
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daily activity. Two patients deteriorated and one 
remained unchanged. The average pre-surgery val-
ue of 56.6% on the Oswestry scale decreased sig-
nificantly during the course of the study to a  lev-
el of 28.9% (p  =  0.000012), giving an average 
improvement of 27.7%. There was also a  signifi-
cant decrease in pain perception. As measured on 
the VAS scale, pain decreased by 4.7 points after 
a mean period of 10 months: the average pain was 
7.8 points prior to surgery, dropping to 3.1 in the 
follow-up (p = 0.00004). There were no neurologi-
cal or general complications, with the exception of 
a transient increase in body temperature (> 38°C) 
in one patient (Fig. 1 and 2).
For the group of 5 patients who were assessed 
between 4.5 and 5 years after PV treatment, the lev-
el of pain relief remained practically unchanged 
since the first follow-up (p = 0.24198 for VAS). In 
3 out of 5 cases, daily activity assessed by means of 
the Oswestry scale worsened, though not signifi-
cantly (p = 0.10881) (Fig. 3 and 4).
Discussion
PV is performed when it can reduce pain and/ 
/or inhibit the progression of pathological frac-
tures of vertebrae. The method is also useful if an 
infiltrating mass is found in a  vertebra that does 
not decrease its height, as prophylaxis against ex-
pected fracture and instability. It is important to 
exclude the presence of tumor masses in the spinal 
canal or in the vertebral foramen, especially in pa-
tients with neurological deficits. In such cases, ver-
tebroplasty may be of limited use and decompres-
sive surgery should be considered, with or without 
appropriate instrumentation to stabilize the spine.
According to the guidelines of the Internation-
al Myeloma Working Group  [2], the indications 
for PV are as follows:
– when severe pain is present (exceeding 7/10 
on the VAS scale) and there is collapse of one or 
more vertebrae, or bone destruction with a  high 
risk of fracture (one or more vertebrae);
– when pain is absent (not exceeding 7/10 on 
the VAS scale) and there is significant loss of ver-
tebral height and/or violation of the structural in-
tegrity or stability of the spine.
Fig. 1. Medium-term follow-up according to the 
Oswestry Scale
Fig. 2. Medium-term follow-up according to VAS
Fig. 3. Long-term follow-up according to the Oswestry 
Scale
Fig. 4. Long-term follow-up according to VAS
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It is important to start treatment as soon as 
possible, i.e., before the onset of spinal deformity. 
Apart from rapid pain control, early vertebroplasty 
significantly improves the quality of the patient’s 
life and precludes the need for the implementation 
of complementary treatments such as radiother-
apy  [4] and analgesic drugs. Additionally, it does 
not interfere with systemic bone marrow suppres-
sive drug therapy [2]. The results of the procedure 
also have a significant impact on the implementa-
tion of adequate physiotherapy.
Between 1 and 4 levels of the spine are usual-
ly treated during a  single PV procedure. Howev-
er, multilevel augmentation requires that the pa-
tients lie in a  prone position for a  considerable 
length of time. And this is not always possible on 
account of the ensuing discomfort and pain. Abso-
lute contraindications for VP include clotting dis-
orders, pregnancy, infection at the planned injec-
tion site, allergy and contraindications for general 
or local anesthesia  [2, 5]. Although most authors 
believe that destruction of the posterior wall of the 
vertebra and penetration of a tumor into the epi-
dural space is a contraindication for PV, successful 
vertebroplasty in such situations has been report-
ed [6]. However, extensive infiltration into the spi-
nal canal or excessive destruction of the vertebral 
body – especially if it is accompanied by a resulting 
neurological deficit – would disqualify a patient for 
VP. Severe collapse of the vertebrae hinders the 
procedure, but does not preclude it [5].
Vertebroplasty can be performed under gener-
al or local anesthesia – or sedoanaglesia using in-
travenous anesthesia and 1% lidocaine at the injec-
tion site. Although general anesthesia affords the 
patient more comfort, local anesthesia allows him 
or her to maintain verbal contact with the surgeon. 
This is particularly important during the insertion 
of the needle. If the positioning is incorrect, the pa-
tient may report radicular pain, which allows im-
mediate correction. In practice, sedoanalgesia is 
sufficient in almost all patients.
Radiofluoroscopic control is necessary in or-
der to carry out PV. The anterioposterior and lat-
eral positions are commonly used. However, the 
procedure can also be performed using computed 
tomography guidance.
The most common injection technique is basal 
placement of the needles either on one or on both 
sides – whichever is possible at the levels of Th3-L5. 
Because of their anatomical structure, higher lev-
els of the spine (above Th2) make the use of the 
percutaneous technique much more difficult. Pro-
cedures involving the cervical and upper thoracic 
spine have been described: C2 using the anterolat-
eral puncture method [7], and Th1 using the open 
method with anterior access [8].
The rate of symptomatic complications ranges 
from 2% to 6.8% [9, 10]. Complications can arise 
from leakage of the cement outside the vertebrae. 
Although this occurs quite often, it does not usual-
ly result in clinically significant symptoms of com-
pression  [11, 12]. Penetration of the cement into 
the paravertebral veins can be dangerous, howev-
er, as it may lead to the rare complication of pul-
monary embolism (in 1.7% of cases). Hematoma 
at the injection site and puncturing of the pleura 
are very rare.
In cases of infiltration of the spinal canal, which 
often results in neurological deficits, decompres-
sive surgery should be considered, as well as stabi-
lization of the spine with the use of implants. The 
results of such treatment are not good, however: 
in patients who cannot move prior to surgery, on-
ly 38% report a  significant improvement in their 
neurological status, while 62% of all patients report 
diminished mobility, notwithstanding decompres-
sion of the spinal cord [13].
The proportion of patients with good analge-
sic results after VP is high, ranging from 67% to 
100%, while up to 70% report an improvement in 
active locomotion [4, 9, 12, 14–16]. The percentage 
of patients in the present study who reported a sig-
nificant reduction of pain was as high as 92.3%. All 
28 articles published to date have reported rapid, 
substantial and consistent pain relief and concom-
itant improvement in the quality of life  [16–23]. 
In the current study group, pain –  as measured 
on the VAS scale –  decreased by 4.7 points af-
ter a  mean period of 10  months. In 23 published 
studies that provided acceptable statistics, the de-
crease in pain was 4.6 VAS points over one year of 
observation [19].
Long-term assessment – i.e., more than 4 years 
after surgery –  is difficult, owing to the course of 
multiple myeloma and the mortality associated 
with the disease. In all 28 of the available studies 
involving thoracic and lumbar augmentation in 
MM, late follow-up has not exceeded 4  years af-
ter the first surgical procedure. The present au-
thors have been able to assess 5 patients between 
4.5 and 5 years after PV treatment. In these cases, 
the reduction in pain has been maintained, while 
the quality of life as measured on the Oswestry 
scale has slightly deteriorated, though to a statisti-
cally insignificant degree. At this stage, these find-
ings cannot be definitive owing to the small num-
ber of patients who have been observed.
Percutaneous kyphoplasty (PK) is also com-
monly used for the treatment of myelomatous ver-
tebral compression fractures. However, the effects 
are comparable with PV and no conclusive data ex-
ists to suggest the superiority of PK as far as pain re-
lief is concerned [19, 24, 25]. PK would seem to be 
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beneficial from a mechanical point of view in order 
to reduce the angle of kyphosis. However, there is 
a lack of evidence to suggest that the quality of life 
of patients who have been treated using this pro-
cedure is any greater than that of those who have 
been treated using percutaneous vertebroplasty.
Another way to treat MM infiltration of ver-
tebral bodies is radiotherapy. Using this method, 
one can limit the infiltration of the cancer, but re-
cent studies have shown that in patients who have 
had PV, radiotherapy does not improve their con-
dition as far as the vertebral column is concerned, 
either in terms of analgesia or in terms of treating 
the underlying disease [26].
The overall results of PV are better in myelo-
ma and metastatic cases than in patients with os-
teoporotic fractures. Recently, two double-blind 
randomized studies have been reported, both fo-
cusing on osteoporotic cases – one comparing PV 
with a  sham intervention involving no injection 
of cement and the other comparing PV with con-
servative treatment  [27, 28]. Surprisingly, these 
reports suggest that PV is no better than a  sh-
am procedure as far as relieving pain or improv-
ing function for patients with vertebral fractures is 
concerned. This positive placebo response is cer-
tainly difficult to explain. In all probability, the re-
sponse to the placebo was encouraged by the same 
ritual in both procedures, a  positive attitude to-
wards the surgeon on the part of the patients and 
also their high expectations concerning the antic-
ipated benefits of PV. On the basis of the placebo 
response hypothesis, therefore, the risk-benefit ra-
tio of PV would not appear to be very favorable. 
However, these findings cannot be extrapolated to 
include myeloma cases, where the pathology of the 
disease is quite different: In MM, progressive bone 
destruction is associated with the failure of new 
bone formation [29].
In two other randomized and controlled stud-
ies that compared the efficacy of PK and PV with 
traditional conservative non-surgical management 
(the FREE 2009 and VERTOS 2010 trials [30, 31]), 
the authors concluded that improvement in the 
quality of life in the kyphoplasty group was great-
er than in the non-surgical group, and also that the 
pain relief afforded by vertebroplasty was signifi-
cantly greater.
On the basis of data from the literature con-
cerning the results of PV in MM [4, 12, 14–16, 18, 
20–24, 26, 29–31] and also on the basis of the pres-
ent authors’ own clinical observations, which show 
that there is a  huge number of patients who are 
very satisfied with the results of this treatment, it 
can be concluded that for the time being, at least, 
it need not be abandoned.
The author concluded that PV is a  minimal-
ly invasive and relatively safe vertebral augmen-
tation procedure for symptomatic vertebral body 
lesions in cases of myeloma. In the majority of cas-
es presenting myeloma infiltration and a  collaps-
ing vertebral body, vertebroplasty is an excellent 
method of achieving pain relief and improving the 
quality of life. Long-term assessment has shown 
consistently good results, though a  greater num-
ber of patients must be observed in order to deter-
mine whether this is really the case. The current 
authors’ own results, along with data from the lit-
erature, have shown that this treatment should be 
continued, as –  unlike the case of PV in patients 
with osteoporosis –  its effectiveness has yet to be 
called into question.
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